DNA methylation is a stable epigenetic modification that contributes to the spatiotemporal
regulation of gene expression. The manner in which DNA methylation contributes to …

A little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein,
survivin, continues to generate intense interest and keen attention from disparate segments …

The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal
haematological diseases characterized by ineffective haematopoiesis and predisposition to …

Purpose The DNA methylation inhibitor 5-aza-2′-deoxycytidine (DAC) is approved for the
treatment of myelodysplastic syndromes (MDS), but resistance to DAC develops during …

Introduction Basal-type, or triple-negative, breast cancer (lacking estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor-2 expression) is a high …

The molecular progression of endometrial cancer is poorly understood, and both genetic
and epigenetic factors play a role. Survivin is a member of the inhibitor of apoptosis (IAP) …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis
presenting with peripheral cytopenias in combination with a hyperplastic bone marrow and …

The approved 7‐day schedule of subcutaneous azacitidine for myelodysplastic syndrome is
associated with injection site reactions and bruising and may be inconvenient because of …

Abstract Purpose of Review An intact DNA damage response is crucial to preventing cancer
development, including in myeloid and lymphoid malignancies. Deficiencies in the …

Lung cancer cells are sensitive to 5-aza-2′-deoxycytidine (decitabine) or midostaurin
(PKC412), because decitabine restores the expression of methylation-silenced tumor …